

A Claims FDA cited, by letter batch
"Same as" / same active ingredient
Use of approved brand names
"Generic"
Implied FDA approval
Firm-branded product
0
20
40
60
80
100
% of letters in batch
Sep 2025 (n = 55)
Feb 2026 (n = 30)
Jun 2026 (n = 25)
B Inter-pass agreement (rules vs reader)
Eligibility
Seller type
Unapproved new drug (505(a))
Compounded-drug advertising or promotion (502(bb))
False/misleading labeling (502(a))
Inadequate directions for use (502(f)(1))
Prescription requirement cited (503(b))
CGMP / insanitary conditions (501(a)(2)(B)/(A))
Sterility assurance
503A conditions not met
503B conditions not met
Salt form / ineligible API
Retatrutide or other unapproved incretin
"Same as" / same active ingredient claim
"Generic" claim
Implied FDA approval claim
Firm-branded product
"Research use" labelling
Offered without prescription
Use of approved brand names
Telehealth / online prescribing features
Inspection-based
Website / social media review
Shortage-list status of recipient's product
0.00
0.25
0.50
0.75
1.00
Agreement, rules vs reader (before adjudication)
Cohen's κ
% agreement / 100